Article Review
This article examines the limited success of mesenchymal stem cells (MSCs) in transforming clinical outcomes through tissue regeneration. While MSCs have demonstrated healing effects, this is not necessarily a critique of the cells themselves but highlights the complexity of wound and regenerative environments that require a systemic approach. Acknowledging that the paracrine effects of implanted MSCs contribute to their therapeutic benefits, the article explores the potential of harnessing these effects for drug delivery in the context of diabetic foot ulcers (DFUs).